These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 35382893)

  • 1. m
    Chen X; Zhou X; Wang X
    Exp Hematol Oncol; 2022 Apr; 11(1):21. PubMed ID: 35382893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The biological function of m6A reader YTHDF2 and its role in human disease.
    Wang JY; Lu AQ
    Cancer Cell Int; 2021 Feb; 21(1):109. PubMed ID: 33593354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. YTHDF2 promotes gallbladder cancer progression and gemcitabine resistance via m6A-dependent DAPK3 degradation.
    Bai X; Chen J; Zhang W; Zhou S; Dong L; Huang J; He X
    Cancer Sci; 2023 Nov; 114(11):4299-4313. PubMed ID: 37700438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pan-cancer analysis identifies YTHDF2 as an immunotherapeutic and prognostic biomarker.
    Liu W; Liu C; You J; Chen Z; Qian C; Lin W; Yu L; Ye L; Zhao L; Zhou R
    Front Cell Dev Biol; 2022; 10():954214. PubMed ID: 36120577
    [No Abstract]   [Full Text] [Related]  

  • 5. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.
    Li J; Xie H; Ying Y; Chen H; Yan H; He L; Xu M; Xu X; Liang Z; Liu B; Wang X; Zheng X; Xie L
    Mol Cancer; 2020 Oct; 19(1):152. PubMed ID: 33121495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of N
    Li J; Meng S; Xu M; Wang S; He L; Xu X; Wang X; Xie L
    Oncotarget; 2018 Jan; 9(3):3752-3764. PubMed ID: 29423080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. YTHDF2 alleviates cardiac hypertrophy via regulating Myh7 mRNA decoy.
    Xu H; Wang Z; Chen M; Zhao W; Tao T; Ma L; Ni Y; Li W
    Cell Biosci; 2021 Jul; 11(1):132. PubMed ID: 34266473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel prognostic implications of YTH domain family 2 in resected hepatocellular carcinoma.
    Nakagawa N; Sonohara F; Tanaka K; Sunagawa Y; Inokawa Y; Takami H; Hayashi M; Yamada S; Kanda M; Tanaka C; Nakayama G; Koike M; Kodera Y
    Oncol Lett; 2021 Jul; 22(1):538. PubMed ID: 34084217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of the KDM5A/miRNA-495/YTHDF2/m6A-MOB3B axis facilitates prostate cancer progression.
    Du C; Lv C; Feng Y; Yu S
    J Exp Clin Cancer Res; 2020 Oct; 39(1):223. PubMed ID: 33087165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-145 Modulates
    Yang Z; Li J; Feng G; Gao S; Wang Y; Zhang S; Liu Y; Ye L; Li Y; Zhang X
    J Biol Chem; 2017 Mar; 292(9):3614-3623. PubMed ID: 28104805
    [No Abstract]   [Full Text] [Related]  

  • 11. Targeting m
    Zhang W; Wu T; Zhang Y; Kang W; Du C; You Q; Chen X; Jiang Z
    Bioorg Med Chem; 2023 Jul; 90():117373. PubMed ID: 37329678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased
    Luo Q; Gao Y; Zhang L; Rao J; Guo Y; Huang Z; Li J
    Biomed Res Int; 2020; 2020():5735279. PubMed ID: 32884942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. YTHDF2, a protein repressed by miR-145, regulates proliferation, apoptosis, and migration in ovarian cancer cells.
    Li J; Wu L; Pei M; Zhang Y
    J Ovarian Res; 2020 Sep; 13(1):111. PubMed ID: 32948220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. YTHDF2 reduction fuels inflammation and vascular abnormalization in hepatocellular carcinoma.
    Hou J; Zhang H; Liu J; Zhao Z; Wang J; Lu Z; Hu B; Zhou J; Zhao Z; Feng M; Zhang H; Shen B; Huang X; Sun B; Smyth MJ; He C; Xia Q
    Mol Cancer; 2019 Nov; 18(1):163. PubMed ID: 31735169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. YTHDF2 exerts tumor-suppressor roles in gastric cancer via up-regulating PPP2CA independently of m
    Zhou Y; Fan K; Dou N; Li L; Wang J; Chen J; Li Y; Gao Y
    Biol Proced Online; 2023 Mar; 25(1):6. PubMed ID: 36870954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. m6A Reader YTHDF2 Regulates LPS-Induced Inflammatory Response.
    Yu R; Li Q; Feng Z; Cai L; Xu Q
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30875984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation.
    Zhang C; Huang S; Zhuang H; Ruan S; Zhou Z; Huang K; Ji F; Ma Z; Hou B; He X
    Oncogene; 2020 Jun; 39(23):4507-4518. PubMed ID: 32366907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Value of YTHDF2 in Clear Cell Renal Cell Carcinoma.
    Mu Z; Dong D; Sun M; Li L; Wei N; Hu B
    Front Oncol; 2020; 10():1566. PubMed ID: 33102202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and Clinical Significance of the m6A RNA-Binding Proteins
    Luo Q; Guo Y; Xiao Q; Fu B; Zhang L; Guo Y; Huang Z; Li J
    Front Med (Lausanne); 2022; 9():922219. PubMed ID: 35755020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ALKBH5 facilitates the progression of infantile hemangioma by increasing FOXF1 expression in a m
    Peng K; Xia RP; Zhao F; Xiao Y; Ma TD; Li M; Feng Y; Zhou CG
    Mol Cell Biochem; 2024 Feb; ():. PubMed ID: 38306011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.